Similar articles for PMID: 10073515

Year	Number of Results
1982	1
1993	1
1994	1
1995	2
1996	4
1997	6
1998	7
1999	9
2000	11
2001	26
2002	18
2003	11
2004	17
2005	9
2006	10
2007	12
2008	9
2009	11
2010	10
2011	3
2012	5
2013	7
2014	11
2015	10
2016	11
2017	8
2018	6
2019	14
2020	2
2021	3
2022	5
2024	0

1

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Aithal GP, Day CP, Kesteven PJ, Daly AK. Aithal GP, et al. Lancet. 1999 Feb 27;353(9154):717-9. doi: 10.1016/S0140-6736(98)04474-2. Lancet. 1999. PMID: 10073515

2

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Higashi MK, et al. JAMA. 2002 Apr 3;287(13):1690-8. doi: 10.1001/jama.287.13.1690. JAMA. 2002. PMID: 11926893

3

Warfarin dose requirement and CYP2C9 polymorphisms.

Halkin H, Lubetsky A. Halkin H, et al. Lancet. 1999 Jun 5;353(9168):1972-3. doi: 10.1016/S0140-6736(05)77184-1. Lancet. 1999. PMID: 10371596 No abstract available.

4

CYP2C9*3 allelic variant and bleeding complications.

Ogg MS, Brennan P, Meade T, Humphries SE. Ogg MS, et al. Lancet. 1999 Sep 25;354(9184):1124. doi: 10.1016/S0140-6736(05)76918-X. Lancet. 1999. PMID: 10509530 Clinical Trial. No abstract available.

5

Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

Taube J, Halsall D, Baglin T. Taube J, et al. Blood. 2000 Sep 1;96(5):1816-9. Blood. 2000. PMID: 10961881 Free article.

6

Genetic modulation of oral anticoagulation with warfarin.

Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G. Margaglione M, et al. Thromb Haemost. 2000 Nov;84(5):775-8. Thromb Haemost. 2000. PMID: 11127854 Clinical Trial.

7

Warfarin dosing and cytochrome P450 2C9 polymorphisms.

Joffe HV, Xu R, Johnson FB, Longtine J, Kucher N, Goldhaber SZ. Joffe HV, et al. Thromb Haemost. 2004 Jun;91(6):1123-8. doi: 10.1160/TH04-02-0083. Thromb Haemost. 2004. PMID: 15175798

8

Interindividual variability in sensitivity to warfarin--Nature or nurture?

Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D. Loebstein R, et al. Clin Pharmacol Ther. 2001 Aug;70(2):159-64. doi: 10.1067/mcp.2001.117444. Clin Pharmacol Ther. 2001. PMID: 11503010

9

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.

Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM. Peyvandi F, et al. Clin Pharmacol Ther. 2004 Mar;75(3):198-203. doi: 10.1016/j.clpt.2003.09.015. Clin Pharmacol Ther. 2004. PMID: 15001971

10

Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.

An SH, Lee KE, Chang BC, Gwak HS. An SH, et al. J Clin Pharm Ther. 2014 Jun;39(3):314-8. doi: 10.1111/jcpt.12143. Epub 2014 Mar 6. J Clin Pharm Ther. 2014. PMID: 24602049

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

245 results

Results by year